An interventional study of Quantitative ATX and LPA determination in plasma and sputum in Rheumatoid Arthritis, sponsored by Hospices Civils de Lyon. Status unknown at 1 site in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-07-27.
Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Basic science
Rheumatoid arthritis (RA) is a common chronic systemic autoimmune relapsing disease characterized by joint inflammation. Beside arthritis leading to progressive joint damage and loss of function, RA is also associated to extraarticular inflammatory conditions such as interstitial lung disease (ILD). This one develops in 30% of all RA patients with a median survival expectancy of 3 to 10 years once symptomatic. Unfortunately, there is no medical care recommendation so far as the pathophysiology is unknown. However, ILD share many similarities with idiopathic pulmonary fibrosis (IPF).
Autotaxin (ATX), due to its lysophospholipase activity, produces a bioactive lipid, lysophosphatidic acid (LPA) under inflammation. LPA has pleiotropic actions inducing cell proliferation, survival, motility and differentiation. Increased ATX and LPA levels have been detected in synovial fluid of RA patients and in IPF patients. ATX is also currently the target for a phase 3 clinical trial in IPF.
Given the previous described role of ATX/LPA axis in arthritis and inflammation-induced bone loss in RA and the similarities between RA-ILD and IPF, the investigators hypothesized that ATX/LPA axis may be also an attractive drug target for this pulmonary condition in RA and therefore that ATX and LPA may be increased in sputum from RA patients with ILD in comparison with sputum from RA patients without ILD.
3,554 studies on the registry are indexed under Arthritis; 317 are open to participants now.
This study's planned enrollment of 40 is below the median of 90 across 2,377 interventional studies indexed under Arthritis.
Browse Arthritis studies →Hospices Civils de Lyon is the lead sponsor of 1,826 studies on the registry; 439 are open to participants now.
Counted across the registry records on this site, refreshed daily.
General inclusion criteria
For female subjects:
Additional inclusion criteria for cases (RA patients with PID):
Additional inclusion criteria for control patients (RA patients without symptomatology without PID)
Exclusion Criteria:
General exclusion criteria
Non-inclusion criteria for cases (RA patients with PID):
Non-inclusion criteria for control patients (RA patients without PID)
Patients with RA and without ILD
Other: Quantitative ATX and LPA determination in plasma and sputum
Patients with RA and ILD
Other: Quantitative ATX and LPA determination in plasma and sputum
Determination of ATX and LPA levels in plasma and sputum from RA-ILD patients ("cases") and in plasma and sputum from RA patients without ILD ("controls") after sputum induction using hypertonic saline inhalation
ATX and LPA levels in sputum from RA patients with ILD in comparison with sputum from RA patients without ILD
All the samples will be frozen and ATX and LPA levels will be assessed in the plasma and sputum at the same time, at the end of the recruitment.
Time frame: Month 30
Correlation between ATX and LPA levels and severity of RA-ILD estimated by tomodensitometry
Determine the correlation between ATX and LPA levels and the severity of CT scan pulmonary involvement\*. \*Diffuse interstitial lung disease is defined as an attack compatible with the thoracic scanner in thin sections according to international criteria with or without associated clinical signs.
Time frame: Month 24
This study is status unknown, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospices Civils de Lyon